Registered title, quoted from ClinicalTrials.gov
68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07914764, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Tumor patients who can obtain the final pathological results.
Inclusion criterion 4
Kidney: GFR > 50 ml/min, ERPF > 280 ml/min, platelet count (PLT) > 75,000/μL, white blood cell (WBC) > 3,000/μL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 3 times the normal value.
Inclusion criterion 5
Red blood cells (RBC) count less than 4×10\^12, white blood cells (WBC) count less than 3×10\^9, hemoglobin level less than 110g/L, and platelet count (PLT) less than 75,000×10\^9;
Exclusion criterion 4
Pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy test result);
Exclusion criterion 9
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07914764, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Volunteer to participate in the trial, with the patient or their legal guardian signing the informed consent form;
- Volunteers are not limited by gender, and the age range is from 18 to 75 years old, inclusive;
- Other imaging examination methods (CT, MRI, etc.) reveal tumor occupying lesions;
- Tumor patients who can obtain the final pathological results.
- Kidney: GFR > 50 ml/min, ERPF > 280 ml/min, platelet count (PLT) > 75,000/μL, white blood cell (WBC) > 3,000/μL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 3 times the normal value.
Exclusion Criteria:
- Individuals with a history of allergy to similar drugs (drugs with similar chemical or biological components to CCK2R), allergic constitution, or current allergic diseases;
- Those who are currently participating in other clinical drug studies, or have previously participated in any clinical drug studies (excluding vitamins and minerals);
- Other uncontrollable clinical issues (such as HIV, hepatitis C virus infection, active hepatitis B, or other severe chronic infections, as well as severe mental, neurological, cardiovascular, respiratory, and other systemic diseases);
- Red blood cells (RBC) count less than 4×10\^12, white blood cells (WBC) count less than 3×10\^9, hemoglobin level less than 110g/L, and platelet count (PLT) less than 75,000×10\^9;
- Obvious abnormalities in liver and kidney function, with GFR less than 50 ml/min;
- Tumor burden greater than 50%, or significant spinal cord compression;
- Expected survival duration less than half a year; chemotherapy within 6 months;
- Having severe acute concomitant diseases or severe treatment-resistant mental disorders;
- Pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy test result);
- Patients who are physically unfit for radiological examinations;
- Other situations where the researcher deems it inappropriate for the participant to participate in the trial.
Quoted from ClinicalTrials.gov, NCT07914764, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07914764, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.